Drugs.com New Drug ApplicationsOriginal article
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
NDA FilingzasocitinibPositive
AI Analysis
Summary
Takeda announced FDA acceptance of its New Drug Application for zasocitinib under Priority Review for the treatment of moderate-to-severe plaque psoriasis. The Priority Review designation indicates potential for an oral treatment option in this indication.
Outcome Details
FDA accepted New Drug Application under Priority Review
Importance:7/10
Sentiment:
0.70
FDANDApriority reviewdermatologyoral therapypsoriasis
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on September 14, 2026 8:09 PM